摘要
目的探讨依洛尤单抗在冠心病患者降脂治疗中的应用效果与安全性。方法抽取2017年1月至2022年6月郑州大学第一附属医院收治的冠心病患者109例,按照用药方案将其分为对照组(42例)与观察组(67例)。对照组给予阿托伐他汀片治疗,观察组在对照组治疗基础上给予依洛尤单抗治疗。比较两组血脂指标、载脂蛋白A1(ApoA1)、载脂蛋白B(ApoB)、肝脏及肾功能指标。结果治疗后,观察组总胆固醇、三酰甘油、低密度脂蛋白胆固醇、ApoB、ApoB/ApoA1低于对照组(t=2.95、3.49、10.07、4.72、6.96,P均<0.05),高密度脂蛋白胆固醇高于对照组(t=2.33,P<0.05),两组丙氨酸氨基转移酶、肌酐水平比较差异未见统计学意义(P>0.05)。结论冠心病患者应用依洛尤单抗治疗,降脂作用良好,且具有较高的安全性,可作为降脂治疗的新方案。
Objective To investigate the effect and safety of evolocumab in the lipid-lowering therapy for coronary heart disease.Methods A total of 109 patients with coronary heart disease admitted to the First Affiliated Hospital of Zhengzhou University from January 2017 to June 2022 were selected,and the patients were divided into control group(42 cases)and observation group(67 cases)according to the medication regimen.The control group was treated with atorvastatin tablets,and the observation group was treated with evolocumab based on the treatment of the control group.The blood lipid indexes,apolipoprotein A1(ApoA1),apolipoprotein B(ApoB),liver and kidney function indexes were compared between the two groups.Results After treatment,the total cholesterol,triacylglycerol,low-density lipoprotein cholesterol,ApoB,ApoB/ApoA1 in the observation group were lower than those in the control group(t=2.95,3.49,10.07,4.72,6.96;all P<0.05),moreover,the high-density lipoprotein cholesterol in the observation group was higher than that in the control group(t=2.33,P<0.05).However,there was no significant difference in levels of alanine aminotransferase and creatinine between the two groups(P>0.05).Conclusions Evolocumab has a good lipid-lowering effect and high safety in the treatment of coronary heart disease.It can be used as a new regimen for lipid-lowering treatment.
作者
王正斌
侯一鸣
赵致慷
黄丽
Wang Zhengbin;Hou Yiming;Zhao Zhikang;Huang Li(Department of Emergency Internal Medicine,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《中国实用医刊》
2023年第10期101-104,共4页
Chinese Journal of Practical Medicine
关键词
冠心病
依洛尤单抗
降脂治疗
血脂指标
Coronary disease
Ilozumab
Lipid-lowering therapy
Blood lipid indexes
作者简介
通信作者:王正斌,Email:zangqu6@126.com。
